Rocket Pharmaceuticals (RCKT) Stock Price, News & Analysis

Company Overview

Rocket Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare, inherited pediatric diseases. The company employs a proprietary adeno-associated virus (AAV) and lentiviral vector platform to deliver functional copies of genes in patients with genetic deficiencies. Its programs target a spectrum of disorders, including Fanconi anemia, leukocyte adhesion deficiency type I and Danon disease, with the goal of delivering one-time treatments that address the underlying causes of disease rather than merely managing symptoms.

The company’s pipeline comprises multiple product candidates in various stages of development. Lead programs such as RP-L102 for Fanconi anemia and RP-L301 for leukocyte adhesion deficiency type I have advanced into clinical trials, where Rocket is evaluating safety and preliminary efficacy. Preclinical efforts include gene therapy candidates for Danon disease and other lysosomal storage disorders. Rocket leverages in-house manufacturing capabilities alongside strategic partnerships to support its clinical and potential commercial supply needs.

Founded in 2015 as a spin-out from academic research institutions, Rocket Pharmaceuticals established its headquarters in New York City. Since inception, the company has expanded its research and development infrastructure to include state-of-the-art manufacturing and clinical trial support facilities. Its management team draws upon expertise in gene therapy development, regulatory strategy and rare disease commercialization to guide programs from laboratory to the clinic.

Rocket Pharmaceuticals serves patient populations primarily in the United States and collaborates with international academic and clinical centers to advance global trial enrollment. The company’s efforts are underpinned by partnerships with nonprofit organizations and academic research groups dedicated to rare disease advocacy, reflecting a commitment to bringing transformative therapies to underserved communities worldwide.

Key Stats

• Today's Range: $4.05 to $4.51
• 50-Day Range: $2.86 to $4.27
• 52-Week Range: $2.19 to $18.89
• Volume: 7.30 million shs
• Average Volume: 3.08 million shs
• Market Capitalization: $457.50 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.67
• Consensus Rating: Hold

Rocket Pharmaceuticals Stock Analysis - MarketRank™

Rocket Pharmaceuticals scored higher than 95% of companies evaluated by MarketBeat, and ranked 50th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Hold

Consensus Rating

Rocket Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 8 buy ratings, 8 hold ratings, and 2 sell ratings.

Upside Potential

Rocket Pharmaceuticals has a consensus price target of $16.67, representing about 293.1% upside from its current price of $4.24.

Amount of Analyst Coverage

Rocket Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Rocket Pharmaceuticals are expected to grow in the coming year, from ($2.83) to ($2.22) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Rocket Pharmaceuticals is -1.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Rocket Pharmaceuticals is -1.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Rocket Pharmaceuticals has a P/B Ratio of 0.83. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

13.80% of the outstanding shares of Rocket Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Rocket Pharmaceuticals has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Rocket Pharmaceuticals has recently decreased by 3.87%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Rocket Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Rocket Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.81

Percentage of Shares Shorted

13.80% of the outstanding shares of Rocket Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Rocket Pharmaceuticals has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Rocket Pharmaceuticals has recently decreased by 3.87%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.71

News Sentiment

Rocket Pharmaceuticals has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Rocket Pharmaceuticals this week, compared to 21 articles on an average week.

Search Interest

Only 21 people have searched for RCKT on MarketBeat in the last 30 days. This is a decrease of -5% compared to the previous 30 days.

MarketBeat Follows

8 people have added Rocket Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.

Company Ownership

• Score: 5.0 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Rocket Pharmaceuticals insiders have sold 214.25% more of their company's stock than they have bought. Specifically, they have bought $34,100.00 in company stock and sold $107,159.00 in company stock.

Percentage Held by Insiders

24.76% of the stock of Rocket Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

98.39% of the stock of Rocket Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

RCKT Stock Analysis - Frequently Asked Questions

How have RCKT shares performed this year?

Rocket Pharmaceuticals' stock was trading at $12.57 at the beginning of 2025. Since then, RCKT stock has decreased by 66.3% and is now trading at $4.24.

How were Rocket Pharmaceuticals' earnings last quarter?

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) announced its quarterly earnings data on Thursday, August, 7th. The biotechnology company reported ($0.59) EPS for the quarter, missing analysts' consensus estimates of ($0.57) by $0.02.

Who are Rocket Pharmaceuticals' major shareholders?

Rocket Pharmaceuticals' top institutional investors include Assenagon Asset Management S.A. (0.03%), CWM LLC (0.03%), Sanders Morris Harris LLC (0.03%) and Voya Investment Management LLC (0.01%). Insiders that own company stock include Gaurav Shah, Gotham Makker, Jonathan David Schwartz, Martin Wilson, Aaron Ondrey, David P Southwell, David P Southwell, Mark Andrew White, John Militello, Elisabeth Bjork and Kinnari Patel.
View institutional ownership trends.

How do I buy shares of Rocket Pharmaceuticals?

Shares of RCKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Rocket Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Rocket Pharmaceuticals investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), Marinus Pharmaceuticals (MRNS), Waste Connections (WCN), Humana (HUM), AUO (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 10/15/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RCKT
• CIK: 1281895
• Web: www.rocketpharma.com
• Phone: (609) 659-8001
• Fax: 646-224-9585
• Employees: 240
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Rocket Pharmaceuticals: $16.67
• High Price Target: $44.00
• Low Price Target: $5.00
• Potential Upside/Downside: +307.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 18 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.51)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$258.75 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -65.11%
• Return on Assets: -55.99%

Debt

• Debt-to-Equity Ratio: 0.05
• Current Ratio: 6.39
• Quick Ratio: 6.39

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.08 per share
• Price / Book: 0.81

Miscellaneous

• Outstanding Shares: 107,900,000
• Free Float: 81,187,000
• Market Cap: $441.53 million
• Optionable: Optionable
• Beta: 0.60